Cargando…

Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma

INTRODUCTION: Recently, several new biological therapies targeted IgE and IL‐5 in severe asthma have been developed and approved. In the last few years, there have been some reports on the therapeutic algorithms for severe asthmatic subjects screened by biomarkers. However, these algorithms have one...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Keiji, Matsunaga, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113769/
https://www.ncbi.nlm.nih.gov/pubmed/30088345
http://dx.doi.org/10.1002/iid3.233
_version_ 1783351071146508288
author Oishi, Keiji
Matsunaga, Kazuto
author_facet Oishi, Keiji
Matsunaga, Kazuto
author_sort Oishi, Keiji
collection PubMed
description INTRODUCTION: Recently, several new biological therapies targeted IgE and IL‐5 in severe asthma have been developed and approved. In the last few years, there have been some reports on the therapeutic algorithms for severe asthmatic subjects screened by biomarkers. However, these algorithms have one problem. In atopic/eosinophilic overlapping asthmatic subjects, there is no effective answer to the question: “which is the optimal choice between Anti‐IgE and anti‐IL‐5?” METHODS: We propose a new three‐step algorithm for biological therapy in severe asthma. RESULTS: Step 1 is to divide subjects into four groups by measuring blood eosinophils and FeNO. Step 2 is to divide the subjects further into six groups by atopy test. In the case of elevated blood eosinophils, normal/elevated FeNO, and atopy, we perform a steroid trial in step 3 in order to decide whether to select anti‐IgE or anti‐IL‐5. The steroid trial is to assess the symptoms of asthma, lung function, blood eosinophils, and FeNO before and after 14 days treatment with 0.5 mg/kg oral prednisolone/day. We judge that cases in which blood eosinophils and FeNO decrease together are not “truely steroid resistance.” In such cases, considering the possibility that allergic type inflammation through adaptive immunity is dominant, anti‐IgE is selected when it is difficult to prevent exacerbations by improving environmental factors. Conversely, we consider that cases in which blood eosinophils and/or FeNO do not decrease, are “truely steroid resistance.” In this case, since there is a possibility that non‐allergic type inflammation due to innate immunity, etc. may remain, anti‐IL‐5, which is expected to be effective for steroid‐resistant eosinophilic inflammation, is selected. CONCLUSIONS: Our three‐step algorithm including the steroid trial may be applicable to companion diagnostics testing for molecularly targeted therapies in severe asthma. Further validation is required to examine the effectiveness of this algorithm.
format Online
Article
Text
id pubmed-6113769
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61137692018-09-04 Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma Oishi, Keiji Matsunaga, Kazuto Immun Inflamm Dis Commentary INTRODUCTION: Recently, several new biological therapies targeted IgE and IL‐5 in severe asthma have been developed and approved. In the last few years, there have been some reports on the therapeutic algorithms for severe asthmatic subjects screened by biomarkers. However, these algorithms have one problem. In atopic/eosinophilic overlapping asthmatic subjects, there is no effective answer to the question: “which is the optimal choice between Anti‐IgE and anti‐IL‐5?” METHODS: We propose a new three‐step algorithm for biological therapy in severe asthma. RESULTS: Step 1 is to divide subjects into four groups by measuring blood eosinophils and FeNO. Step 2 is to divide the subjects further into six groups by atopy test. In the case of elevated blood eosinophils, normal/elevated FeNO, and atopy, we perform a steroid trial in step 3 in order to decide whether to select anti‐IgE or anti‐IL‐5. The steroid trial is to assess the symptoms of asthma, lung function, blood eosinophils, and FeNO before and after 14 days treatment with 0.5 mg/kg oral prednisolone/day. We judge that cases in which blood eosinophils and FeNO decrease together are not “truely steroid resistance.” In such cases, considering the possibility that allergic type inflammation through adaptive immunity is dominant, anti‐IgE is selected when it is difficult to prevent exacerbations by improving environmental factors. Conversely, we consider that cases in which blood eosinophils and/or FeNO do not decrease, are “truely steroid resistance.” In this case, since there is a possibility that non‐allergic type inflammation due to innate immunity, etc. may remain, anti‐IL‐5, which is expected to be effective for steroid‐resistant eosinophilic inflammation, is selected. CONCLUSIONS: Our three‐step algorithm including the steroid trial may be applicable to companion diagnostics testing for molecularly targeted therapies in severe asthma. Further validation is required to examine the effectiveness of this algorithm. John Wiley and Sons Inc. 2018-08-07 /pmc/articles/PMC6113769/ /pubmed/30088345 http://dx.doi.org/10.1002/iid3.233 Text en © 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Oishi, Keiji
Matsunaga, Kazuto
Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title_full Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title_fullStr Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title_full_unstemmed Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title_short Three‐step algorithm for biological therapy targeted IgE and IL‐5 in severe asthma
title_sort three‐step algorithm for biological therapy targeted ige and il‐5 in severe asthma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113769/
https://www.ncbi.nlm.nih.gov/pubmed/30088345
http://dx.doi.org/10.1002/iid3.233
work_keys_str_mv AT oishikeiji threestepalgorithmforbiologicaltherapytargetedigeandil5insevereasthma
AT matsunagakazuto threestepalgorithmforbiologicaltherapytargetedigeandil5insevereasthma